Skip to Content

Prolensa Approval History

  • FDA approved: Yes (First approved April 5th, 2013)
  • Brand name: Prolensa
  • Generic name: bromfenac
  • Dosage form: Ophthalmic Solution
  • Company: Bausch + Lomb
  • Treatment for: Postoperative Ocular Inflammation

Prolensa (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Development History and FDA Approval Process for Prolensa

Apr  8, 2013Approval Bausch + Lomb Receives FDA Approval for Prolensa

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.